Der neue Ford Fiesta ST: eine Fahrspaß-Maschine mit Zylinder-Deaktivierung und Fahrdynamik-Programmen
Köln (ots) - - Optional mit mechanischem Sperrdifferenzial für angetriebene Vorderachse verfügbar - ...
Münster (ots) - Passend zum heutigen Geburtstag der Modepuppe Barbie konnte ein Eurojackpot-Spieler aus Berlin ...
Hamburg (ots) - Persönliche Gespräche und Pressemitteilungen sind nach wie vor die wichtigsten ...
Hong Kong And Ft Lauderdale, Florida (ots/PRNewswire) - OrbusNeich Medical, Inc. ("OrbusNeich"), a designer, developer, manufacturer and marketer of innovative medical devices for the treatment of vascular diseases, announced today that on May 13, 2015, it prevailed in a final opposition appeal hearing in the European Patent Office ("EPO") regarding European Patent EP 1 341 482 - STENT HAVING HELICAL ELEMENTS ('482). The '482 patent has withstood the highest level of review in the EPO and has been upheld as a valid patent in amended form.
In a related matter, OrbusNeich announced that it had filed suit in Germany in the District Court Duesseldorf and in the Netherlands regarding patent infringement of the '482 patent by Terumo and their Ultimaster[TM] Drug Eluting Stent. A request for a preliminary injunction banning distribution of the Ultimaster Drug Eluting Stent has been filed in Germany.
"Our intellectual property represents the creativity of OrbusNeich employees. We have spent considerable resources creating our IP portfolio which is one of the base assets of companies operating in this industry. We don't view ourselves as a particularly litigious company, but as we have demonstrated in the past, we will vigorously defend our intellectual property." said Wayne Johnson, President and Chief Executive Officer of OrbusNeich.
About OrbusNeich - Pioneers in life-changing technologies
OrbusNeich is a global pioneer in the provision of life-changing vascular solutions and offers an extensive portfolio of products that set industry benchmarks in vascular intervention. Current products are the world's first dual therapy stent, the COMBO Dual Therapy Stent, and the world's first pro-healing stent, the Genous(TM) Stent. Other products include stents and balloons marketed under the names of Azule(TM), R Stent(TM), Scoreflex(TM), Sapphire(TM) II, Sapphire(TM) II Pro and Sapphire(TM) II NC. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Florida, USA.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.
Learn more about our life-changing technologies on our social media channels:
Contact: Keith Hummel, +1(212)474-1772, KHummel@cravath.comOriginal-Content von: OrbusNeich, übermittelt durch news aktuell